<DOC>
	<DOCNO>NCT00692926</DOCNO>
	<brief_summary>The main purpose investigational ( approved FDA ) Phase I research test whether transplantation umbilical cord blood cell safely supplement transfusion portion cell sort ( collect special machine call cell sorter ) either infused hour standard transplant patient grow special system laboratory prior transplant , design increase number stem cell transplant . This system currently early phase test .</brief_summary>
	<brief_title>Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells</brief_title>
	<detailed_description>The main purpose study test whether transplantation umbilical cord blood cell safely supplement transfusion portion cell grow special system ( design increase number cell transplant ) laboratory prior transplant . This system currently early phase test FDA-IND-sponsored clinical trial . If patient consent participate study , approximately 1/5th ( 20 % ) cord blood unit select transplant treat per protocol . The first 3 patient receive ALDHbr sort cell primed culture . This test safety ALDHbr cell . The treated cell give patient day transplant approximately 4 hour standard conventional transplant give 80 % fraction cord blood unit . A total 26 evaluable patient enrol outline ( protocol amend allow enrollment ) : - 10 evaluable patient receive ALDHbr freshly sort cell ( 20 % portion ) - 10 evaluable patient receive ALDHbr sort cytokine prim cell ( 20 % portion ) - 3 evaluable patient receive conventional cord blood unit cord blood unit ALDHbr sort ( sort UCB unit do Day -1 due time take actually perform sort ) - 3 evaluable patient receive conventional cord blood unit cord blood unit ALDHbr sort cytokine prim ( sort prim do day -5 described later protocol )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>Hematologic Malignancy : High risk ALL first complete remission ALL ANLL second subsequent remission ANLL relapse MDS CML chronic phase accelerate phase Severe aplastic anemia refractory medical therapy The subject negative CNS disease time enrollment . Inborn error metabolism Hurler Syndrome ( MPS I ) HurlerScheie Syndrome Hunter Syndrome ( MPS II ) Sanfilippo Syndrome ( MPS III ) Morquio Syndrome ( MPS IV ) MaroteauxLamy Syndrome ( MPS VI ) Krabbe Disease ( Globoid Leukodystrophy ) Metachromatic Leukodystrophy ( MLD ) Adrenoleukodystrophy ( ALD AMN ) Sandhoff Disease Tay Sachs Disease The subject NOT uncontrolled seizure , apnea , evidence aspiration pneumonia evidence brain stem involvement MRI scan Congenital marrow failure Amegakaryocytic thrombocytopenia TAR Kostmann 's Syndrome SchwachmanDiamond Syndrome BlackfanDiamond Anemia Congenital immunodeficiency syndrome require myeloablative therapy Wiscott Aldrich Syndrome LAD CGD FEL/HLH CVID/CID SUBJECT 'S DONOR Subject NOT 6/6 5/6 antigen match related bone marrow donor . Suitably match cord blood unit adequate cell dose available . Unit must dual compartment bag . PERFORMANCE STATUS ORGAN FUNCTION &lt; 55 year age time enrollment . Lansky score 60 % 100 % , Karnofsky score 50 % 100 % Adequate function organ system Creatinine &lt; 2.0 mg/dl creatinine clearance &gt; 50 cc/min/m2 Hepatic transaminase ( ALT/AST ) &lt; 4 x normal , bilirubin &lt; 2.0 mg/dl Normal cardiac function echocardiogram radionuclide scan Pulmonary function test demonstrate FVC , CVC , FEV1 &gt; 60 % predicted age . For adult patient DLCO &gt; 60 % predict . If patient perform PFTs , clearance pediatric adult pulmonologist require No uncontrolled infection time cytoreduction NOT pregnant lactating ( must current negative pregnancy test ) HIV negative Subject concurrently involve clinical trial affect engraftment immune reconstitution ( e.g . hematopoietic growth factor ) . Subject comorbid condition , view Principal Investigators , render patient high risk treatment complication regimen related morbidity/mortality .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ALDHbr</keyword>
	<keyword>Umbilical Cord Blood</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Hematological malignancy</keyword>
	<keyword>MDS</keyword>
	<keyword>severe aplastic anemia</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>congenital marrow failure congenital immunodeficiency syndrome</keyword>
	<keyword>Hurler 's Disease</keyword>
	<keyword>Tay Sach 's</keyword>
	<keyword>PMD</keyword>
	<keyword>Hunter 's Syndrome</keyword>
	<keyword>Krabbe</keyword>
	<keyword>MLD</keyword>
	<keyword>ALD</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
</DOC>